These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19728172)

  • 1. Expression, purification, and C-terminal site-specific PEGylation of cysteine-mutated glucagon-like peptide-1.
    Gao M; Tian H; Ma C; Gao X; Guo W; Yao W
    Appl Biochem Biotechnol; 2010 Sep; 162(1):155-65. PubMed ID: 19728172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris.
    Dou WF; Lei JY; Zhang LF; Xu ZH; Chen Y; Jin J
    Protein Expr Purif; 2008 Sep; 61(1):45-9. PubMed ID: 18556214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microwave-assisted solid phase synthesis, PEGylation, and biological activity studies of glucagon-like peptide-1(7-36) amide.
    Chi Y; Zhang H; Huang W; Zhou J; Zhou Y; Qian H; Ni S
    Bioorg Med Chem; 2008 Aug; 16(16):7607-14. PubMed ID: 18656368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
    Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1.
    Zhang ZZ; Yang SS; Dou H; Mao JF; Li KS
    Protein Expr Purif; 2004 Aug; 36(2):292-9. PubMed ID: 15249052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
    Kumar M; Hunag Y; Glinka Y; Prud'homme GJ; Wang Q
    Gene Ther; 2007 Jan; 14(2):162-72. PubMed ID: 16943856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
    Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
    Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
    Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
    Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of a fusion protein containing eight GLP-1 analogues produced in Escherichia coli BL21(DE3) in streptozotocin-induced diabetic rats.
    Hou J; Yan R; Ding D; Yang L; Wang C; Wu Z; Yu X; Li W; Li M
    Biotechnol Lett; 2007 Oct; 29(10):1439-46. PubMed ID: 17581704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
    Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
    Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
    Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
    J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High cell density cultivation of recombinant Escherichia coli for prodrug of recombinant human GLPs production.
    Zhou Y; Ma X; Hou Z; Xue X; Meng J; Li M; Jia M; Luo X
    Protein Expr Purif; 2012 Sep; 85(1):38-43. PubMed ID: 22771632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli.
    Yin X; Wei D; Yi L; Tao X; Ma Y
    Protein Expr Purif; 2005 Jun; 41(2):259-65. PubMed ID: 15866711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
    Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a kallikrein-like protease from the snake venom: engineering of autocatalytic site in the fusion protein to facilitate protein refolding.
    Hung CC; Chiou SH
    Biochem Biophys Res Commun; 2000 Sep; 275(3):924-30. PubMed ID: 10973823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and solid-phase refolding of human glucagon-like peptide-1 using recombinant Escherichia coli.
    Kim SG; Shin SY; Park YC; Shin CS; Seo JH
    Protein Expr Purif; 2011 Aug; 78(2):197-203. PubMed ID: 21421051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
    Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
    Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of prokaryotic expression plasmid pET15b-PEP-1-CAT and expression and purification of PEP-1-CAT fusion protein].
    Yao LL; Wang JN; Huang YZ; Guo LY
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1319-25. PubMed ID: 16982446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
    Riedel MJ; Lee CW; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.